首页 > 最新文献

Science Signaling最新文献

英文 中文
TB impairs DNA repair. 结核病会损害 DNA 修复。
IF 7.3 1区 生物学 Pub Date : 2023-12-19 DOI: 10.1126/scisignal.adn5031
Annalisa M VanHook

A Mycobacterium tuberculosis virulence factor promotes foam cell formation by inhibiting DNA repair.

一种结核分枝杆菌毒力因子通过抑制 DNA 修复促进泡沫细胞的形成。
{"title":"TB impairs DNA repair.","authors":"Annalisa M VanHook","doi":"10.1126/scisignal.adn5031","DOIUrl":"10.1126/scisignal.adn5031","url":null,"abstract":"<p><p>A <i>Mycobacterium tuberculosis</i> virulence factor promotes foam cell formation by inhibiting DNA repair.</p>","PeriodicalId":49560,"journal":{"name":"Science Signaling","volume":null,"pages":null},"PeriodicalIF":7.3,"publicationDate":"2023-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138812483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inhibition of the lysine demethylase LSD1 modulates the balance between inflammatory and antiviral responses against coronaviruses. 抑制赖氨酸去甲基化酶 LSD1 可调节针对冠状病毒的炎症反应和抗病毒反应之间的平衡。
IF 7.3 1区 生物学 Pub Date : 2023-12-19 DOI: 10.1126/scisignal.ade0326
Luca Mazzarella, Fabio Santoro, Roberto Ravasio, Valeria Fumagalli, Paul E Massa, Simona Rodighiero, Elena Gavilán, Mauro Romanenghi, Bruno A Duso, Emanuele Bonetti, Lara Manganaro, Rani Pallavi, Deborah Trastulli, Isabella Pallavicini, Claudia Gentile, Silvia Monzani, Tommaso Leonardi, Sebastiano Pasqualato, Gabriele Buttinelli, Angela Di Martino, Giorgio Fedele, Ilaria Schiavoni, Paola Stefanelli, Giuseppe Meroni, Raffaele de Francesco, Christian Steinkuhler, Gianluca Fossati, Matteo Iannacone, Saverio Minucci, Pier Giuseppe Pelicci

Innate immune responses to coronavirus infections are highly cell specific. Tissue-resident macrophages, which are infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients but are inconsistently infected in vitro, exert critical but conflicting effects by secreting both antiviral type I interferons (IFNs) and tissue-damaging inflammatory cytokines. Steroids, the only class of host-targeting drugs approved for the treatment of coronavirus disease 2019 (COVID-19), indiscriminately suppress both responses, possibly impairing viral clearance. Here, we established in vitro cell culture systems that enabled us to separately investigate the cell-intrinsic and cell-extrinsic proinflammatory and antiviral activities of mouse macrophages infected with the prototypical murine coronavirus MHV-A59. We showed that the nuclear factor κB-dependent inflammatory response to viral infection was selectively inhibited by loss of the lysine demethylase LSD1, which was previously implicated in innate immune responses to cancer, with negligible effects on the antiviral IFN response. LSD1 ablation also enhanced an IFN-independent antiviral response, blocking viral egress through the lysosomal pathway. The macrophage-intrinsic antiviral and anti-inflammatory activity of Lsd1 inhibition was confirmed in vitro and in a humanized mouse model of SARS-CoV-2 infection. These results suggest that LSD1 controls innate immune responses against coronaviruses at multiple levels and provide a mechanistic rationale for potentially repurposing LSD1 inhibitors for COVID-19 treatment.

对冠状病毒感染的先天免疫反应具有高度的细胞特异性。组织驻留的巨噬细胞在患者体内感染严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2),但在体外感染的情况并不一致,它们通过分泌抗病毒 I 型干扰素(IFNs)和组织损伤性炎性细胞因子,发挥关键但相互矛盾的作用。类固醇是唯一一类被批准用于治疗 2019 年冠状病毒病(COVID-19)的宿主靶向药物,它不加区分地抑制这两种反应,可能会损害病毒清除。在这里,我们建立了体外细胞培养系统,使我们能够分别研究小鼠巨噬细胞感染原型小鼠冠状病毒MHV-A59后的细胞内和细胞外促炎和抗病毒活性。我们发现,赖氨酸去甲基化酶 LSD1 的缺失会选择性地抑制对病毒感染的核因子κB 依赖性炎症反应,而对抗病毒 IFN 反应的影响微乎其微。LSD1 消减还增强了不依赖于 IFN 的抗病毒反应,阻断了病毒通过溶酶体途径的排出。在体外和人源化小鼠 SARS-CoV-2 感染模型中证实了抑制 Lsd1 的巨噬细胞内在抗病毒和抗炎活性。这些结果表明,LSD1 在多个水平上控制着针对冠状病毒的先天免疫反应,并为可能将 LSD1 抑制剂重新用于 COVID-19 治疗提供了机理依据。
{"title":"Inhibition of the lysine demethylase LSD1 modulates the balance between inflammatory and antiviral responses against coronaviruses.","authors":"Luca Mazzarella, Fabio Santoro, Roberto Ravasio, Valeria Fumagalli, Paul E Massa, Simona Rodighiero, Elena Gavilán, Mauro Romanenghi, Bruno A Duso, Emanuele Bonetti, Lara Manganaro, Rani Pallavi, Deborah Trastulli, Isabella Pallavicini, Claudia Gentile, Silvia Monzani, Tommaso Leonardi, Sebastiano Pasqualato, Gabriele Buttinelli, Angela Di Martino, Giorgio Fedele, Ilaria Schiavoni, Paola Stefanelli, Giuseppe Meroni, Raffaele de Francesco, Christian Steinkuhler, Gianluca Fossati, Matteo Iannacone, Saverio Minucci, Pier Giuseppe Pelicci","doi":"10.1126/scisignal.ade0326","DOIUrl":"10.1126/scisignal.ade0326","url":null,"abstract":"<p><p>Innate immune responses to coronavirus infections are highly cell specific. Tissue-resident macrophages, which are infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients but are inconsistently infected in vitro, exert critical but conflicting effects by secreting both antiviral type I interferons (IFNs) and tissue-damaging inflammatory cytokines. Steroids, the only class of host-targeting drugs approved for the treatment of coronavirus disease 2019 (COVID-19), indiscriminately suppress both responses, possibly impairing viral clearance. Here, we established in vitro cell culture systems that enabled us to separately investigate the cell-intrinsic and cell-extrinsic proinflammatory and antiviral activities of mouse macrophages infected with the prototypical murine coronavirus MHV-A59. We showed that the nuclear factor κB-dependent inflammatory response to viral infection was selectively inhibited by loss of the lysine demethylase LSD1, which was previously implicated in innate immune responses to cancer, with negligible effects on the antiviral IFN response. LSD1 ablation also enhanced an IFN-independent antiviral response, blocking viral egress through the lysosomal pathway. The macrophage-intrinsic antiviral and anti-inflammatory activity of Lsd1 inhibition was confirmed in vitro and in a humanized mouse model of SARS-CoV-2 infection. These results suggest that LSD1 controls innate immune responses against coronaviruses at multiple levels and provide a mechanistic rationale for potentially repurposing LSD1 inhibitors for COVID-19 treatment.</p>","PeriodicalId":49560,"journal":{"name":"Science Signaling","volume":null,"pages":null},"PeriodicalIF":7.3,"publicationDate":"2023-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138812462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
RHOAL57V drives the development of diffuse gastric cancer through IGF1R-PAK1-YAP1 signaling. RHOAL57V通过IGF1R-PAK1-YAP1信号传导驱动弥漫性胃癌的发展。
IF 7.3 1区 生物学 Pub Date : 2023-12-19 DOI: 10.1126/scisignal.adg5289
Antje Schaefer, Richard G Hodge, Haisheng Zhang, G Aaron Hobbs, Julien Dilly, Minh V Huynh, Craig M Goodwin, Feifei Zhang, J Nathaniel Diehl, Mariaelena Pierobon, Elisa Baldelli, Sehrish Javaid, Karson Guthrie, Naim U Rashid, Emanuel F Petricoin, Adrienne D Cox, William C Hahn, Andrew J Aguirre, Adam J Bass, Channing J Der

Cancer-associated mutations in the guanosine triphosphatase (GTPase) RHOA are found at different locations from the mutational hotspots in the structurally and biochemically related RAS. Tyr42-to-Cys (Y42C) and Leu57-to-Val (L57V) substitutions are the two most prevalent RHOA mutations in diffuse gastric cancer (DGC). RHOAY42C exhibits a gain-of-function phenotype and is an oncogenic driver in DGC. Here, we determined how RHOAL57V promotes DGC growth. In mouse gastric organoids with deletion of Cdh1, which encodes the cell adhesion protein E-cadherin, the expression of RHOAL57V, but not of wild-type RHOA, induced an abnormal morphology similar to that of patient-derived DGC organoids. RHOAL57V also exhibited a gain-of-function phenotype and promoted F-actin stress fiber formation and cell migration. RHOAL57V retained interaction with effectors but exhibited impaired RHOA-intrinsic and GAP-catalyzed GTP hydrolysis, which favored formation of the active GTP-bound state. Introduction of missense mutations at KRAS residues analogous to Tyr42 and Leu57 in RHOA did not activate KRAS oncogenic potential, indicating distinct functional effects in otherwise highly related GTPases. Both RHOA mutants stimulated the transcriptional co-activator YAP1 through actin dynamics to promote DGC progression; however, RHOAL57V additionally did so by activating the kinases IGF1R and PAK1, distinct from the FAK-mediated mechanism induced by RHOAY42C. Our results reveal that RHOAL57V and RHOAY42C drive the development of DGC through distinct biochemical and signaling mechanisms.

鸟苷三磷酸酶(GTP酶)RHOA的癌症相关突变与结构和生化相关的RAS的突变热点位置不同。Tyr42-to-Cys(Y42C)和Leu57-to-Val(L57V)取代是弥漫性胃癌(DGC)中最常见的两种RHOA突变。RHOAY42C 表现出功能增益表型,是 DGC 的致癌驱动因子。在这里,我们确定了RHOAL57V是如何促进DGC生长的。在缺失了编码细胞粘附蛋白E-cadherin的Cdh1的小鼠胃器官组织中,表达RHOAL57V(而非野生型RHOA)会诱发与患者衍生的DGC器官组织相似的异常形态。RHOAL57V还表现出功能增益表型,并促进了F-肌动蛋白应力纤维的形成和细胞迁移。RHOAL57V 保留了与效应物的相互作用,但表现出 RHOA 内在和 GAP 催化的 GTP 水解功能受损,这有利于活性 GTP 结合态的形成。在与 RHOA 中 Tyr42 和 Leu57 类似的 KRAS 残基上引入错义突变不会激活 KRAS 的致癌潜能,这表明在其他高度相关的 GTP 酶中存在不同的功能效应。两种 RHOA 突变体都通过肌动蛋白动力学刺激转录共激活因子 YAP1,从而促进 DGC 的进展;然而,RHOAL57V 还通过激活激酶 IGF1R 和 PAK1 来达到这一目的,这与 RHOAY42C 诱导的 FAK 介导的机制不同。我们的研究结果表明,RHOAL57V和RHOAY42C通过不同的生化和信号机制驱动DGC的发展。
{"title":"RHOA<sup>L57V</sup> drives the development of diffuse gastric cancer through IGF1R-PAK1-YAP1 signaling.","authors":"Antje Schaefer, Richard G Hodge, Haisheng Zhang, G Aaron Hobbs, Julien Dilly, Minh V Huynh, Craig M Goodwin, Feifei Zhang, J Nathaniel Diehl, Mariaelena Pierobon, Elisa Baldelli, Sehrish Javaid, Karson Guthrie, Naim U Rashid, Emanuel F Petricoin, Adrienne D Cox, William C Hahn, Andrew J Aguirre, Adam J Bass, Channing J Der","doi":"10.1126/scisignal.adg5289","DOIUrl":"10.1126/scisignal.adg5289","url":null,"abstract":"<p><p>Cancer-associated mutations in the guanosine triphosphatase (GTPase) RHOA are found at different locations from the mutational hotspots in the structurally and biochemically related RAS. Tyr<sup>42</sup>-to-Cys (Y42C) and Leu<sup>57</sup>-to-Val (L57V) substitutions are the two most prevalent RHOA mutations in diffuse gastric cancer (DGC). RHOA<sup>Y42C</sup> exhibits a gain-of-function phenotype and is an oncogenic driver in DGC. Here, we determined how RHOA<sup>L57V</sup> promotes DGC growth. In mouse gastric organoids with deletion of <i>Cdh1</i>, which encodes the cell adhesion protein E-cadherin, the expression of RHOA<sup>L57V</sup>, but not of wild-type RHOA, induced an abnormal morphology similar to that of patient-derived DGC organoids. RHOA<sup>L57V</sup> also exhibited a gain-of-function phenotype and promoted F-actin stress fiber formation and cell migration. RHOA<sup>L57V</sup> retained interaction with effectors but exhibited impaired RHOA-intrinsic and GAP-catalyzed GTP hydrolysis, which favored formation of the active GTP-bound state. Introduction of missense mutations at KRAS residues analogous to Tyr<sup>42</sup> and Leu<sup>57</sup> in RHOA did not activate KRAS oncogenic potential, indicating distinct functional effects in otherwise highly related GTPases. Both RHOA mutants stimulated the transcriptional co-activator YAP1 through actin dynamics to promote DGC progression; however, RHOA<sup>L57V</sup> additionally did so by activating the kinases IGF1R and PAK1, distinct from the FAK-mediated mechanism induced by RHOA<sup>Y42C</sup>. Our results reveal that RHOA<sup>L57V</sup> and RHOA<sup>Y42C</sup> drive the development of DGC through distinct biochemical and signaling mechanisms.</p>","PeriodicalId":49560,"journal":{"name":"Science Signaling","volume":null,"pages":null},"PeriodicalIF":7.3,"publicationDate":"2023-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10791543/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138812482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A noncanonical IRAK4-IRAK1 pathway counters DNA damage-induced apoptosis independently of TLR/IL-1R signaling. 独立于 TLR/IL-1R 信号的非经典 IRAK4-IRAK1 通路可对抗 DNA 损伤诱导的细胞凋亡。
IF 7.3 1区 生物学 Pub Date : 2023-12-19 DOI: 10.1126/scisignal.adh3449
Yuanyuan Li, Richa B Shah, Samanta Sarti, Alicia L Belcher, Brian J Lee, Andrej Gorbatenko, Francesca Nemati, Honglin Yu, Zoe Stanley, Mahbuba Rahman, Zhengping Shao, Jose M Silva, Shan Zha, Samuel Sidi

Interleukin-1 receptor (IL-1R)-associated kinases (IRAKs) are core effectors of Toll-like receptors (TLRs) and IL-1R in innate immunity. Here, we found that IRAK4 and IRAK1 together inhibited DNA damage-induced cell death independently of TLR or IL-1R signaling. In human cancer cells, IRAK4 was activated downstream of ATR kinase in response to double-strand breaks (DSBs) induced by ionizing radiation (IR). Activated IRAK4 then formed a complex with and activated IRAK1. The formation of this complex required the E3 ubiquitin ligase Pellino1, acting structurally but not catalytically, and the activation of IRAK1 occurred independently of extracellular signaling, intracellular TLRs, and the TLR/IL-1R signaling adaptor MyD88. Activated IRAK1 translocated to the nucleus in a Pellino2-dependent manner. In the nucleus, IRAK1 bound to the PIDD1 subunit of the proapoptotic PIDDosome and interfered with platform assembly, thus supporting cell survival. This noncanonical IRAK signaling pathway was also activated in response to other DSB-inducing agents. The loss of IRAK4, of IRAK4 kinase activity, of either Pellino protein, or of the nuclear localization sequence in IRAK1 sensitized p53-mutant zebrafish to radiation. Thus, the findings may lead to strategies for overcoming tumor resistance to conventional cancer treatments.

白细胞介素-1受体(IL-1R)相关激酶(IRAK)是先天性免疫中Toll样受体(TLR)和IL-1R的核心效应因子。在这里,我们发现IRAK4和IRAK1共同抑制DNA损伤诱导的细胞死亡,而不受TLR或IL-1R信号转导的影响。在人类癌细胞中,当电离辐射(IR)诱导双链断裂(DSB)时,IRAK4在ATR激酶下游被激活。活化的 IRAK4 随后与 IRAK1 形成复合物并活化 IRAK1。该复合物的形成需要E3泛素连接酶Pellino1,Pellino1在结构上起作用而不是催化作用,IRAK1的活化不受细胞外信号、细胞内TLR和TLR/IL-1R信号适配体MyD88的影响。活化的 IRAK1 以 Pellino2 依赖性方式转位到细胞核。在细胞核中,IRAK1 与促凋亡 PIDDosome 的 PIDD1 亚基结合,干扰平台组装,从而支持细胞存活。这种非经典的IRAK信号通路在其他DSB诱导剂的作用下也会被激活。IRAK4、IRAK4激酶活性、Pellino蛋白或IRAK1核定位序列的缺失使p53突变斑马鱼对辐射敏感。因此,这些发现可能会为克服肿瘤对常规癌症治疗的抗药性提供策略。
{"title":"A noncanonical IRAK4-IRAK1 pathway counters DNA damage-induced apoptosis independently of TLR/IL-1R signaling.","authors":"Yuanyuan Li, Richa B Shah, Samanta Sarti, Alicia L Belcher, Brian J Lee, Andrej Gorbatenko, Francesca Nemati, Honglin Yu, Zoe Stanley, Mahbuba Rahman, Zhengping Shao, Jose M Silva, Shan Zha, Samuel Sidi","doi":"10.1126/scisignal.adh3449","DOIUrl":"10.1126/scisignal.adh3449","url":null,"abstract":"<p><p>Interleukin-1 receptor (IL-1R)-associated kinases (IRAKs) are core effectors of Toll-like receptors (TLRs) and IL-1R in innate immunity. Here, we found that IRAK4 and IRAK1 together inhibited DNA damage-induced cell death independently of TLR or IL-1R signaling. In human cancer cells, IRAK4 was activated downstream of ATR kinase in response to double-strand breaks (DSBs) induced by ionizing radiation (IR). Activated IRAK4 then formed a complex with and activated IRAK1. The formation of this complex required the E3 ubiquitin ligase Pellino1, acting structurally but not catalytically, and the activation of IRAK1 occurred independently of extracellular signaling, intracellular TLRs, and the TLR/IL-1R signaling adaptor MyD88. Activated IRAK1 translocated to the nucleus in a Pellino2-dependent manner. In the nucleus, IRAK1 bound to the PIDD1 subunit of the proapoptotic PIDDosome and interfered with platform assembly, thus supporting cell survival. This noncanonical IRAK signaling pathway was also activated in response to other DSB-inducing agents. The loss of IRAK4, of IRAK4 kinase activity, of either Pellino protein, or of the nuclear localization sequence in IRAK1 sensitized p53-mutant zebrafish to radiation. Thus, the findings may lead to strategies for overcoming tumor resistance to conventional cancer treatments.</p>","PeriodicalId":49560,"journal":{"name":"Science Signaling","volume":null,"pages":null},"PeriodicalIF":7.3,"publicationDate":"2023-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11111193/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138812461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
RHOA drivers take alternate routes in gastric cancer. RHOA 司机在胃癌患者中另辟蹊径。
IF 7.3 1区 生物学 Pub Date : 2023-12-19 DOI: 10.1126/scisignal.adk9171
Dorothy Benton, Jonathan Chernoff

Oncogenic small guanosine triphosphatases (GTPases) are often characterized by a limited set of activating mutations that affect their intrinsic biochemical function, but RHOA-which is frequently mutated in gastric cancer-appears not to have read the instruction manual. Having previously characterized the Y42C RHOA mutation in gastric cancer, in this issue of Science Signaling, Schaefer et al. take on the slightly less common L57V mutation and find that individual RHOA mutations can have different and unpredictable signaling outcomes.

致癌的小鸟苷三磷酸酶(GTP酶)通常以一组影响其内在生化功能的有限激活突变为特征,但在胃癌中经常发生突变的RHOA似乎并没有阅读说明书。Schaefer 等人之前研究了胃癌中的 Y42C RHOA 突变,在本期的《科学信号》(Science Signaling)杂志上,他们研究了稍不常见的 L57V 突变,发现单个 RHOA 突变会产生不同的、不可预测的信号转导结果。
{"title":"RHOA drivers take alternate routes in gastric cancer.","authors":"Dorothy Benton, Jonathan Chernoff","doi":"10.1126/scisignal.adk9171","DOIUrl":"10.1126/scisignal.adk9171","url":null,"abstract":"<p><p>Oncogenic small guanosine triphosphatases (GTPases) are often characterized by a limited set of activating mutations that affect their intrinsic biochemical function, but RHOA-which is frequently mutated in gastric cancer-appears not to have read the instruction manual. Having previously characterized the Y42C RHOA mutation in gastric cancer, in this issue of <i>Science Signaling</i>, Schaefer <i>et al.</i> take on the slightly less common L57V mutation and find that individual RHOA mutations can have different and unpredictable signaling outcomes.</p>","PeriodicalId":49560,"journal":{"name":"Science Signaling","volume":null,"pages":null},"PeriodicalIF":7.3,"publicationDate":"2023-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138812481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstract PR-009: Targeting the sterol regulatory element-binding protein pathway in pancreatic ductal adenocarcinoma PR-009:靶向胰腺导管腺癌中固醇调控元件结合蛋白通路
IF 7.3 1区 生物学 Pub Date : 2021-11-15 DOI: 10.1158/1538-7445.panca21-pr-009
S. Myers, Meredith R. McGuire, W. Shao, Chin-Shei Liu, Theodore E. Ewachiw, Z. Rasheed, W. Matsui, Toni Sepalla, R. Burkhart, P. Espenshade
{"title":"Abstract PR-009: Targeting the sterol regulatory element-binding protein pathway in pancreatic ductal adenocarcinoma","authors":"S. Myers, Meredith R. McGuire, W. Shao, Chin-Shei Liu, Theodore E. Ewachiw, Z. Rasheed, W. Matsui, Toni Sepalla, R. Burkhart, P. Espenshade","doi":"10.1158/1538-7445.panca21-pr-009","DOIUrl":"https://doi.org/10.1158/1538-7445.panca21-pr-009","url":null,"abstract":"","PeriodicalId":49560,"journal":{"name":"Science Signaling","volume":null,"pages":null},"PeriodicalIF":7.3,"publicationDate":"2021-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88822724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstract PO-094: Gα13 loss in KPC mouse model promotes well-differentiated pancreatic tumors that are susceptible to mTOR inhibition 摘要PO-094: Gα13缺失在KPC小鼠模型中促进了易受mTOR抑制的胰腺高分化肿瘤
IF 7.3 1区 生物学 Pub Date : 2021-11-15 DOI: 10.1158/1538-7445.panca21-po-094
M. Shields, Christina Spaulding, Mahmoud G. Khalafalla, Thao N. D. Pham, H. Munshi
{"title":"Abstract PO-094: Gα13 loss in KPC mouse model promotes well-differentiated pancreatic tumors that are susceptible to mTOR inhibition","authors":"M. Shields, Christina Spaulding, Mahmoud G. Khalafalla, Thao N. D. Pham, H. Munshi","doi":"10.1158/1538-7445.panca21-po-094","DOIUrl":"https://doi.org/10.1158/1538-7445.panca21-po-094","url":null,"abstract":"","PeriodicalId":49560,"journal":{"name":"Science Signaling","volume":null,"pages":null},"PeriodicalIF":7.3,"publicationDate":"2021-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81191725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstract PO-091: Histamine receptor 1 (HRH1): A potentially novel G protein-coupled receptor (GPCR) therapeutic target in pancreatic adenocarcinoma (PDAC) cells and tumors PO-091:组胺受体1 (HRH1):一种潜在的新型G蛋白偶联受体(GPCR)治疗胰腺癌(PDAC)细胞和肿瘤的靶点
IF 7.3 1区 生物学 Pub Date : 2021-11-15 DOI: 10.1158/1538-7445.panca21-po-091
C. Salmerón, K. Sriram, M. Javadi‐Paydar, P. Insel
A recent study reported that patients taking HRH1 antihistamines have decreased progression of various tumors, including PDAC; the authors inferred that this was an immune effect (Fritz et al., PMID: 33550204). We have initiated studies to test an alternative hypothesis: HRH1 expressed by PDAC cells may contribute to the malignant phenotype and if so, FDA-approved HRH1 antihistamines might be therapeutics to treat or perhaps prevent PDAC. We have undertaken bioinformatic and experimental approaches to test this hypothesis. Our bioinformatic analysis revealed that PDAC tumors in The Cancer Genome Atlas (TCGA) have >30-fold higher HRH1 expression than in normal pancreas (GTEx database) and is highly expressed in PDAC cell lines in the Cancer Cell Line Encyclopedia (CCLE). HRH1 expression was selectively associated with markers of PDAC cells and not with markers of other cell types in the tumor microenvironment. Higher expression of HRH1 in TCGA-PDAC tumors negatively impacts on patient survival. Our experimental studies indicate that human and mouse PDAC cells express HRH1 mRNA, protein and signaling and that HRH1 is present on the surface of PDAC cells. We found that histamine prominently increases calcium [Ca2+] in multiple human PDAC cell lines with EC50 values comparable to that in other cell types. The histamine-stimulated increase in [Ca2+] occurs via a Gq/11 (heterotrimeric GTP binding protein)-dependent mechanism and is blocked by multiple FDA-approved HRH1 antihistamines (with pKi values similar to those of HRH1 inhibition of other cell types). HRH1 activation by histamine increases PDAC cell migration. Histamine also increases the production of numerous cytokines (including VEGF) from PDAC cells, and in preliminary studies, stimulates growth of multiple PDAC cell lines at low concentrations (1-10 nM). Together with published data indicating that mast cells (which synthesize and release histamine) in PDAC tumors are associated with PDAC cell growth/invasion, angiogenesis and worse prognosis, our findings suggest that independent of immune cells, a "mast cell-histamine-PDAC cell HRH1 axis" may contribute to the malignant phenotype of PDAC tumors. Importantly, HRH1 on PDAC cells could be targeted by repurposing approved HRH1 antihistamines as a novel therapeutic approach for PDAC tumors. Supported by grants from the University of California Cancer Research Coordinating Committee and Tobacco-Related Disease Research Program. Citation Format: Cristina Salmeron, Krishna Sriram, Mehrak Javadi-Paydar, Paul A. Insel. Histamine receptor 1 (HRH1): A potentially novel G protein-coupled receptor (GPCR) therapeutic target in pancreatic adenocarcinoma (PDAC) cells and tumors [abstract]. In: Proceedings of the AACR Virtual Special Conference on Pancreatic Cancer; 2021 Sep 29-30. Philadelphia (PA): AACR; Cancer Res 2021;81(22 Suppl):Abstract nr PO-091.
最近的一项研究报道,服用HRH1抗组胺药的患者可以减少各种肿瘤的进展,包括PDAC;作者推断这是一种免疫效应(Fritz et al., PMID: 33550204)。我们已经启动了一项研究来验证另一种假设:由PDAC细胞表达的HRH1可能导致恶性表型,如果是这样,fda批准的HRH1抗组胺药可能是治疗或预防PDAC的治疗药物。我们采用了生物信息学和实验方法来检验这一假设。我们的生物信息学分析显示,癌症基因组图谱(TCGA)中的PDAC肿瘤的HRH1表达量比正常胰腺(GTEx数据库)高30倍以上,并且在癌症细胞系百科全书(CCLE)中的PDAC细胞系中高表达。HRH1的表达选择性地与PDAC细胞的标记物相关,而与肿瘤微环境中其他细胞类型的标记物无关。HRH1在TCGA-PDAC肿瘤中的高表达会对患者的生存产生负面影响。我们的实验研究表明,人和小鼠PDAC细胞表达HRH1 mRNA、蛋白和信号,并且HRH1存在于PDAC细胞表面。我们发现组胺显著增加多种人类PDAC细胞系中的钙[Ca2+],其EC50值与其他细胞类型相当。组胺刺激的[Ca2+]增加通过Gq/11(异源三聚体GTP结合蛋白)依赖机制发生,并被多种fda批准的HRH1抗组胺药阻断(pKi值与其他细胞类型的HRH1抑制相似)。组胺激活HRH1增加PDAC细胞迁移。组胺还可以增加PDAC细胞中多种细胞因子(包括VEGF)的产生,在初步研究中,在低浓度(1-10 nM)下,组胺可以刺激多种PDAC细胞系的生长。结合已发表的数据表明,PDAC肿瘤中的肥大细胞(合成并释放组胺)与PDAC细胞的生长/侵袭、血管生成和更差的预后相关,我们的研究结果表明,独立于免疫细胞的“肥大细胞-组胺-PDAC细胞HRH1轴”可能有助于PDAC肿瘤的恶性表型。重要的是,通过重新利用已批准的HRH1抗组胺药作为PDAC肿瘤的新治疗方法,可以靶向PDAC细胞上的HRH1。由加州大学癌症研究协调委员会和烟草相关疾病研究项目资助。引文格式:Cristina Salmeron, Krishna Sriram, Mehrak Javadi-Paydar, Paul A. Insel。组胺受体1 (HRH1):一种潜在的新型G蛋白偶联受体(GPCR)治疗胰腺腺癌(PDAC)细胞和肿瘤的靶点[摘要]。摘自:AACR胰腺癌虚拟特别会议论文集;2021年9月29-30日。费城(PA): AACR;癌症杂志,2021;81(22增刊):摘要nr PO-091。
{"title":"Abstract PO-091: Histamine receptor 1 (HRH1): A potentially novel G protein-coupled receptor (GPCR) therapeutic target in pancreatic adenocarcinoma (PDAC) cells and tumors","authors":"C. Salmerón, K. Sriram, M. Javadi‐Paydar, P. Insel","doi":"10.1158/1538-7445.panca21-po-091","DOIUrl":"https://doi.org/10.1158/1538-7445.panca21-po-091","url":null,"abstract":"A recent study reported that patients taking HRH1 antihistamines have decreased progression of various tumors, including PDAC; the authors inferred that this was an immune effect (Fritz et al., PMID: 33550204). We have initiated studies to test an alternative hypothesis: HRH1 expressed by PDAC cells may contribute to the malignant phenotype and if so, FDA-approved HRH1 antihistamines might be therapeutics to treat or perhaps prevent PDAC. We have undertaken bioinformatic and experimental approaches to test this hypothesis. Our bioinformatic analysis revealed that PDAC tumors in The Cancer Genome Atlas (TCGA) have >30-fold higher HRH1 expression than in normal pancreas (GTEx database) and is highly expressed in PDAC cell lines in the Cancer Cell Line Encyclopedia (CCLE). HRH1 expression was selectively associated with markers of PDAC cells and not with markers of other cell types in the tumor microenvironment. Higher expression of HRH1 in TCGA-PDAC tumors negatively impacts on patient survival. Our experimental studies indicate that human and mouse PDAC cells express HRH1 mRNA, protein and signaling and that HRH1 is present on the surface of PDAC cells. We found that histamine prominently increases calcium [Ca2+] in multiple human PDAC cell lines with EC50 values comparable to that in other cell types. The histamine-stimulated increase in [Ca2+] occurs via a Gq/11 (heterotrimeric GTP binding protein)-dependent mechanism and is blocked by multiple FDA-approved HRH1 antihistamines (with pKi values similar to those of HRH1 inhibition of other cell types). HRH1 activation by histamine increases PDAC cell migration. Histamine also increases the production of numerous cytokines (including VEGF) from PDAC cells, and in preliminary studies, stimulates growth of multiple PDAC cell lines at low concentrations (1-10 nM). Together with published data indicating that mast cells (which synthesize and release histamine) in PDAC tumors are associated with PDAC cell growth/invasion, angiogenesis and worse prognosis, our findings suggest that independent of immune cells, a \"mast cell-histamine-PDAC cell HRH1 axis\" may contribute to the malignant phenotype of PDAC tumors. Importantly, HRH1 on PDAC cells could be targeted by repurposing approved HRH1 antihistamines as a novel therapeutic approach for PDAC tumors. Supported by grants from the University of California Cancer Research Coordinating Committee and Tobacco-Related Disease Research Program. Citation Format: Cristina Salmeron, Krishna Sriram, Mehrak Javadi-Paydar, Paul A. Insel. Histamine receptor 1 (HRH1): A potentially novel G protein-coupled receptor (GPCR) therapeutic target in pancreatic adenocarcinoma (PDAC) cells and tumors [abstract]. In: Proceedings of the AACR Virtual Special Conference on Pancreatic Cancer; 2021 Sep 29-30. Philadelphia (PA): AACR; Cancer Res 2021;81(22 Suppl):Abstract nr PO-091.","PeriodicalId":49560,"journal":{"name":"Science Signaling","volume":null,"pages":null},"PeriodicalIF":7.3,"publicationDate":"2021-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77781268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstract PO-092: Influence of the IL-13-receptor alpha 1 chain on the malignant phenotype of pancreatic cancer cells 摘要PO-092: il -13受体α 1链对胰腺癌细胞恶性表型的影响
IF 7.3 1区 生物学 Pub Date : 2021-11-15 DOI: 10.1158/1538-7445.panca21-po-092
Jingwei Shi, M. Kornmann, B. Traub
{"title":"Abstract PO-092: Influence of the IL-13-receptor alpha 1 chain on the malignant phenotype of pancreatic cancer cells","authors":"Jingwei Shi, M. Kornmann, B. Traub","doi":"10.1158/1538-7445.panca21-po-092","DOIUrl":"https://doi.org/10.1158/1538-7445.panca21-po-092","url":null,"abstract":"","PeriodicalId":49560,"journal":{"name":"Science Signaling","volume":null,"pages":null},"PeriodicalIF":7.3,"publicationDate":"2021-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81718317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstract PO-081: Studying MYC's contribution to replication stress at the nuclear pore 摘要:PO-081:研究MYC对核孔复制胁迫的贡献
IF 7.3 1区 生物学 Pub Date : 2021-11-15 DOI: 10.1158/1538-7445.panca21-po-081
G. Cohn, Colin J. Daniel, Daniel F. Liefwalker, R. Sears
{"title":"Abstract PO-081: Studying MYC's contribution to replication stress at the nuclear pore","authors":"G. Cohn, Colin J. Daniel, Daniel F. Liefwalker, R. Sears","doi":"10.1158/1538-7445.panca21-po-081","DOIUrl":"https://doi.org/10.1158/1538-7445.panca21-po-081","url":null,"abstract":"","PeriodicalId":49560,"journal":{"name":"Science Signaling","volume":null,"pages":null},"PeriodicalIF":7.3,"publicationDate":"2021-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88132474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Science Signaling
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1